[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 25 of about 25
1. Santos-García D, Prieto JM, Lema M: [Clinical course of multiple sclerosis in patients treated with cytostatic drugs for cancer]. Rev Neurol; 2009 Jan 16-31;48(2):71-4
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical course of multiple sclerosis in patients treated with cytostatic drugs for cancer].
  • INTRODUCTION: The risk of side effects secondary to global and non-specific immune suppression has limited the systematic application of immunosuppressive therapy in multiple sclerosis (MS).
  • However, when a patient with MS develops a cancer, cytostatic drugs as treatment for the neoplastic process may induce improvement not only of the cancer but also of MS.
  • CASE REPORTS: We present a series of four women with clinically defined MS and subjected to cytostatic therapy (cisplatin, 5-fluorouracil, leukovorin, adriamycin, tamoxifen and anastrozole) after the development of cancer: two presented breast cancer, one colon cancer, and the fourth parotid gland malignancy.
  • Their clinical and neuroimaging course is described, following chemotherapy for the malignant disease.
  • The four women have improved and remain clinically stable after neoplastic treatment.
  • At the present one patient receives weekly intramuscular interferon-beta 1a, whereas the other did not received any treatment.
  • Immunosuppressive therapy could be a therapeutic option among patients with an aggressive clinical course.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain / pathology. Cytostatic Agents / therapeutic use. Multiple Sclerosis, Chronic Progressive / pathology. Multiple Sclerosis, Relapsing-Remitting / pathology. Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / complications. Adenocarcinoma / drug therapy. Adenocarcinoma / surgery. Adult. Breast Neoplasms / complications. Breast Neoplasms / drug therapy. Breast Neoplasms / radiotherapy. Breast Neoplasms / surgery. Carcinoma, Acinar Cell / complications. Carcinoma, Acinar Cell / drug therapy. Carcinoma, Ductal, Breast / complications. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / radiotherapy. Carcinoma, Ductal, Breast / surgery. Cisplatin / administration & dosage. Colonic Neoplasms / complications. Colonic Neoplasms / drug therapy. Colonic Neoplasms / surgery. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Immunosuppressive Agents / adverse effects. Immunosuppressive Agents / therapeutic use. Leucovorin / administration & dosage. Magnetic Resonance Imaging. Methylprednisolone / adverse effects. Methylprednisolone / therapeutic use. Nitriles / administration & dosage. Parotid Neoplasms / complications. Parotid Neoplasms / drug therapy. Parotid Neoplasms / radiotherapy. Parotid Neoplasms / surgery. Tamoxifen / administration & dosage. Triazoles / administration & dosage

  • Genetic Alliance. consumer health - Multiple Sclerosis.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. ANASTROZOLE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19173204.001).
  • [ISSN] 1576-6578
  • [Journal-full-title] Revista de neurologia
  • [ISO-abbreviation] Rev Neurol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cytostatic Agents; 0 / Immunosuppressive Agents; 0 / Nitriles; 0 / Triazoles; 094ZI81Y45 / Tamoxifen; 2Z07MYW1AZ / anastrozole; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


2. Dahse R, Kosmehl H: Detection of drug-sensitizing EGFR exon 19 deletion mutations in salivary gland carcinoma. Br J Cancer; 2008 Jul 8;99(1):90-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of drug-sensitizing EGFR exon 19 deletion mutations in salivary gland carcinoma.
  • Activating mutations within the epidermal growth factor receptor (EGFR) identify lung adenocarcinoma patients with improved clinical responses to tyrosine kinase inhibitors gefitinib and erlotinib.
  • By screening salivary gland carcinoma, two drug-sensitizing EGFR exon 19 delE746-A750 mutations were identified in an adenocystic and in a mucoepidermoid carcinoma of the parotid gland.
  • [MeSH-major] Drug Resistance / genetics. Parotid Neoplasms / drug therapy. Parotid Neoplasms / genetics. Protein Kinase Inhibitors / therapeutic use. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Aged. Carcinoma, Adenoid Cystic / drug therapy. Carcinoma, Adenoid Cystic / genetics. Carcinoma, Mucoepidermoid / drug therapy. Carcinoma, Mucoepidermoid / genetics. DNA, Neoplasm / genetics. Erlotinib Hydrochloride. Exons. Female. Humans. Male. Middle Aged. Mutation. Quinazolines / therapeutic use

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] J Mol Diagn. 2005 Aug;7(3):396-403 [16049312.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):5900-9 [16043828.001]
  • [Cites] J Clin Oncol. 2007 Sep 1;25(25):3978-84 [17761983.001]
  • [Cites] Clin Cancer Res. 2006 Jul 1;12(13):3908-14 [16818686.001]
  • [Cites] Pathol Int. 2007 May;57(5):233-44 [17493170.001]
  • [Cites] Oral Oncol. 2007 Sep;43(8):729-34 [17350323.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):839-44 [16467097.001]
  • (PMID = 18542074.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  • [Other-IDs] NLM/ PMC2453031
  •  go-up   go-down


3. Hsu HC, Huang EY, Eng HL: Cheek mass as a presentation of metastatic rectal cancer. Chang Gung Med J; 2002 May;25(5):345-8
Genetic Alliance. consumer health - Metastatic cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Computed tomographic (CT) scan showed a well-defined 5 x 5-cm mass over the right parotid space and infratemporal fossa.
  • Histology of this right cheek mass revealed it to be a metastatic adenocarcinoma, which was similar to that of the primary rectal adenocarcinoma.
  • Chemotherapy was not considered due to her advanced age.
  • She did not complete the entire radiation therapy course because she expired.
  • [MeSH-minor] Aged. Female. Humans. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12141709.001).
  • [ISSN] 2072-0939
  • [Journal-full-title] Chang Gung medical journal
  • [ISO-abbreviation] Chang Gung Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


Advertisement
4. Furusawa J, Mizumati T, Iizuka K: [A case of parotid carcinoma with hepatic metastasis that responded remarkably to combination chemotherapy of docetaxel, cisplatin and 5-fluorouracil]. Gan To Kagaku Ryoho; 2003 Dec;30(13):2097-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of parotid carcinoma with hepatic metastasis that responded remarkably to combination chemotherapy of docetaxel, cisplatin and 5-fluorouracil].
  • A patient who had parotid gland carcinoma with hepatic metastasis (T4N2bM1) underwent 3 cycles of neoadjuvant chemotherapy with docetaxel, cisplatin and fluorouracil (TPF).
  • After this treatment, the patient showed a PR in the primary site and a CR in the hepatic metastasis.
  • Left total parotidectomy and modified radical neck dissection were then performed followed by postoperative irradiation of 40 Gy.
  • No recurrence in the primary site or the neck was seen, but in the metastatic site a recurrence was observed at 8 weeks after the first chemotherapy.
  • The same chemotherapy is now applied in an outpatient setting.
  • TPF is considered to show clinical activity for advanced parotid gland carcinoma, and we consider further investigation necessary.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Parotid Neoplasms / pathology
  • [MeSH-minor] Cisplatin / administration & dosage. Drug Administration Schedule. Fluorouracil / administration & dosage. Humans. Lymphatic Metastasis. Male. Middle Aged. Neck Dissection. Taxoids / administration & dosage

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14712771.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


5. Chou R, Chen A, Lau D: Complete response of brain metastases to irinotecan-based chemotherapy. J Clin Neurosci; 2005 Apr;12(3):242-5
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete response of brain metastases to irinotecan-based chemotherapy.
  • Currently, radiotherapy and surgery are the mainstay of palliative therapy for patients with brain metastases, while the role of systemic chemotherapy remains uncertain.
  • In this article, we report complete responses to irinotecan-based chemotherapy in three patients with brain metastases from parotid adenocarcinoma, esophageal adenocarcinoma and small cell lung cancer.
  • Irinotecan-based chemotherapy may hold promise in treating patients with brain metastases.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / secondary. Camptothecin / analogs & derivatives
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Carcinoma, Small Cell / pathology. Carcinoma, Small Cell / surgery. Esophageal Neoplasms / pathology. Esophageal Neoplasms / surgery. Female. Humans. Lung Neoplasms / pathology. Lung Neoplasms / surgery. Magnetic Resonance Imaging. Male. Middle Aged. Parotid Neoplasms / pathology. Parotid Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15851073.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


6. Doi K, Kinoshita T, Asano T: [A case with parotid carcinoma showing a pathologically complete response after treatment with S-1 alone]. Gan To Kagaku Ryoho; 2010 Sep;37(9):1759-61

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case with parotid carcinoma showing a pathologically complete response after treatment with S-1 alone].
  • We report a 57-year-old male case of adenocarcinoma of the parotid gland with metastases to the cervical lymph nodes (T3N2bM0, Stage IV A).
  • After 4 courses of S-1, PET findings showed a remarkable regression of the tumor resulting in a partial response (PR) for the primary lesion.
  • After this treatment, partial parotidectomy and upper neck dissection were performed.
  • [MeSH-major] Oxonic Acid / therapeutic use. Parotid Neoplasms / drug therapy. Parotid Neoplasms / pathology. Tegafur / therapeutic use
  • [MeSH-minor] Biopsy. Combined Modality Therapy. Drug Combinations. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Positron-Emission Tomography. Remission Induction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20841941.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


7. Piechocki MP, Lonardo F, Ensley JF, Nguyen T, Kim H, Yoo GH: Anticancer activity of docetaxel in murine salivary gland carcinoma. Clin Cancer Res; 2002 Mar;8(3):870-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anticancer activity of docetaxel in murine salivary gland carcinoma.
  • PURPOSE: The purpose of this study was to evaluate the biological mechanisms of docetaxel (TXT) on salivary gland carcinoma.
  • RESULTS: We characterized a spontaneous mouse salivary gland carcinoma (SGC1).
  • SGC1 is a poorly differentiated carcinoma that originated from the parotid gland of a BALB/c mouse.
  • CONCLUSIONS: We have identified several novel targets of TXT that contribute to its antitumor activity in poorly differentiated salivary gland carcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Phytogenic / therapeutic use. Paclitaxel / analogs & derivatives. Paclitaxel / therapeutic use. Salivary Gland Neoplasms / drug therapy. Taxoids
  • [MeSH-minor] Animals. Antigens, CD95 / metabolism. Apoptosis / drug effects. Blotting, Western. Cell Communication / drug effects. Cell Cycle / drug effects. Cell Division / drug effects. Connexin 43 / metabolism. Female. Flow Cytometry. Fluorescent Antibody Technique. Gap Junctions / drug effects. Immunoenzyme Techniques. Keratins / metabolism. Mice. Mice, Inbred BALB C. Mice, SCID. Precipitin Tests. Proliferating Cell Nuclear Antigen / metabolism. S100 Proteins / metabolism. Tumor Cells, Cultured / drug effects

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11895921.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / Antineoplastic Agents, Phytogenic; 0 / Connexin 43; 0 / Proliferating Cell Nuclear Antigen; 0 / S100 Proteins; 0 / S100A1 protein; 0 / Taxoids; 15H5577CQD / docetaxel; 68238-35-7 / Keratins; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


8. Christensen NR, Charabi S, Johansen LS, Rygaard J, Balle VH, Tos M, Thomsen J: Effect of photodynamic therapy on a heterotransplanted human parotid tumor. Auris Nasus Larynx; 2000 Jul;27(3):241-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of photodynamic therapy on a heterotransplanted human parotid tumor.
  • To evaluate the effect of photodynamic therapy on human parotid tumors we used tumor specimens obtained from parotid surgery on a consecutive group of patients.
  • The original human tumors were pleomorphic adenoma (four), adenolymphoma (one), acinic cell carcinoma (one), sarcoma (one) and low-grade adenocarcinoma (one).
  • The most aggressive growth was seen in the low-grade adenocarcinoma.
  • We re-implanted this tumor on ten mice bilaterally, and treated the tumors with photodynamic therapy (PDT), resulting in a mean depth of tumor necrosis of 5.4 mm (1-10 mm).
  • In three cases we found vital tumor cells in the periphery of the tumor after treatment, with several new blood vessels in the surrounding tissue, indicating a great potential for neo-angiogenesis in this tumor.
  • In order to evaluate the possible nerve damage subsequent to the photodynamic therapy, the ischiadic nerve in 24 lower limbs of nude mice were investigated.
  • The current study demonstrates that the nude mice implantation model is excellent to investigate growth in both malignant and benign parotid tumors, and to test new therapeutic modalities.
  • Photodynamic therapy seems to have a possible role in the future management of the malignant lesions of the parotid gland, in cases where radical surgery for some reason is not achievable.
  • [MeSH-major] Neoplasm Transplantation. Parotid Neoplasms / drug therapy. Photochemotherapy. Transplantation, Heterologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10808112.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] NETHERLANDS
  •  go-up   go-down


9. Shimane T, Mori T, Ono T, Egawa S, Furuta A, Ikeda K, Kamakazu K, Kobayashi S, Sanbe T, Suzaki H: [Three cases of adenocarcinoma of the head and neck maintaining QOL by administration of docetaxel]. Gan To Kagaku Ryoho; 2010 Dec;37(13):2897-900
Hazardous Substances Data Bank. DOCETAXEL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Three cases of adenocarcinoma of the head and neck maintaining QOL by administration of docetaxel].
  • A primary head and neck adenocarcinoma is a comparatively rare disease, and surgical resection has been the first choice for its treatment.
  • In the present study, we performed chemotherapy with weekly administration of docetaxel in 3 cases with unresectable or recurrent adenocarcinoma of the head and neck on an outpatient basis, resulting in long-term maintenance of the patients' QOL.
  • Each case had submandibular gland carcinoma, parotid gland carcinoma, or parathyroid gland carcinoma.
  • The present results might suggest that it is possible to treat patients with adenocarcinoma in the head and neck without decreasing patients' QOL.
  • [MeSH-major] Adenocarcinoma / drug therapy. Head and Neck Neoplasms / drug therapy. Taxoids / administration & dosage
  • [MeSH-minor] Adult. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Quality of Life

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21160265.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel
  •  go-up   go-down


10. Kariya S, Kosaka M, Orita Y, Akagi H, Nishizaki K: Adenocarcinoma ex pleomorphic adenoma of the head and neck: Report of five cases. Auris Nasus Larynx; 2006 Mar;33(1):43-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma ex pleomorphic adenoma of the head and neck: Report of five cases.
  • OBJECTIVE: Adenocarcinoma ex pleomorphic adenoma is a rare tumor, and thus the management of the tumor has not been established.
  • RESULTS: We present five cases of adenocarcinoma ex pleomorphic adenoma of the head and neck, including a rare case with nasopharyngeal adenocarcinoma ex pleomorphic adenoma.
  • There was no response to chemotherapy with nedaplatin and 5-FU, but the nasopharyngeal adenocarcinoma ex pleomorphic adenoma showed a remarkable regression after the administration of docetaxel.
  • CONCLUSION: The combination therapy that includes docetaxel may be a promising treatment for adenocarcinoma ex pleomorphic adenoma of the head and neck.
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoadjuvant Therapy. Organoplatinum Compounds / administration & dosage. Palate / pathology. Parotid Gland / pathology. Retrospective Studies. Taxoids / administration & dosage

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16168590.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 0 / Taxoids; 15H5577CQD / docetaxel; 8UQ3W6JXAN / nedaplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


11. Manor E, Sion-Vardy N, Bodner L: Cytogenetic and fluorescence in situ hybridization analysis of a basal cell adenocarcinoma of the mandible. Cancer Genet Cytogenet; 2006 Apr 15;166(2):186-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetic and fluorescence in situ hybridization analysis of a basal cell adenocarcinoma of the mandible.
  • Basal cell adenocarcinoma (BCAC) of the salivary glands is rare.
  • Distant metastasis to the mandible from a salivary gland tumor is also considered rare.
  • An 80-year-old female with primary BCAC of the parotid salivary gland underwent parotidectomy and chemotherapy.
  • Tissue specimens from the mandibular lesion were tested by the following pathologic methods: hematoxylin-eosin and immunohistochemistry for CK8/18, CK/903, vimentin, and smooth muscle actin.
  • The characteristic histologic architecture of BCAC found in the mandible was similar to that of the earlier findings of the tumor in the parotid gland.
  • Trisomy 4 was also found in the paraffin-embedded samples of the primary parotid tumor.
  • [MeSH-major] Adenocarcinoma / genetics. Mandibular Neoplasms / genetics
  • [MeSH-minor] Aged, 80 and over. Chromosome Inversion / genetics. Chromosomes, Human, Pair 4 / genetics. Female. Humans. In Situ Hybridization, Fluorescence. Parotid Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16631478.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Katsurago N, Shiraishi Y, Hashizume M, Miyasaka Y: [Long-term survival following multimodality treatment of metachronous metastases (parotid gland, adrenal gland, brain and mediastinal lymph node) after resection of non-small cell lung cancer; report of a case]. Kyobu Geka; 2006 Feb;59(2):168-71
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term survival following multimodality treatment of metachronous metastases (parotid gland, adrenal gland, brain and mediastinal lymph node) after resection of non-small cell lung cancer; report of a case].
  • We describe a case of long-term survival following multimodality treatment of metachronous metastases (parotid gland, adrenal gland, brain and mediastinal lymph node) after resection of non-small cell lung cancer.
  • A 72-year-old man had a past history of right upper lobectomy for pT3N0M0 tubular adenocarcinoma of the lung 12 years ago and left lower lobectomy for pT3N1M0 papillary adenocarcinoma of the lung 42 months ago, and left parotidectomy and irradiation to the neck for parotid metastasis 20 months ago.
  • He underwent adrenalectomy and gamma knife surgery and received irradiation to the mediastinum, and was administered gefitinib as first-line chemotherapy for about a year.
  • Brain metastases recurred despite 4 more rounds of gamma knife surgery and 4 cycles of docetaxel hydrate as second-line chemotherapy, and 1 cycle of vinorelbine ditartrate as third-line chemotherapy.
  • We confirm the possibility of long-term survival following multimodality treatment even though multiple organ metastases were found after resection of non-small cell lung cancer.
  • [MeSH-major] Adrenal Gland Neoplasms / secondary. Adrenal Gland Neoplasms / therapy. Brain Neoplasms / secondary. Brain Neoplasms / therapy. Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / surgery. Parotid Neoplasms / secondary. Parotid Neoplasms / therapy
  • [MeSH-minor] Aged. Combined Modality Therapy. Fatal Outcome. Humans. Lymphatic Metastasis. Male. Mediastinum. Pneumonectomy. Survival. Time Factors. Treatment Outcome


13. Maruya S, Namba A, Matsubara A, Kakehata S, Takeda I, Shirasaki T, Hatayama Y, Nagahata M, Yokoyama J, Shinkawa H: Salivary gland carcinoma treated with concomitant chemoradiation with intraarterial cisplatin and docetaxel. Int J Clin Oncol; 2006 Oct;11(5):403-6
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salivary gland carcinoma treated with concomitant chemoradiation with intraarterial cisplatin and docetaxel.
  • Malignant neoplasms of the salivary gland are uncommon entities in which surgical resection of the primary lesion has been accepted as a standard therapeutic option.
  • The efficacy of radiation and systemic chemotherapy has been limited for patients with recurrent, metastatic, or unresectable disease because of unfavorable response rates and the short duration of the response.
  • We treated one patient with recurrent adenoid cystic carcinoma arising from the sublingual gland and one patient with primary adenocarcinoma arising from the parotid gland with transfemoral intraarterial chemotherapy, based on full-dose cisplatin and docetaxel and concurrent external-beam radiotherapy.
  • The concomitant chemoradiotherapy of cisplatin and docetaxel seemed to be a practicable option for patients with recurrent and unresectable salivary gland carcinomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Parotid Neoplasms / drug therapy. Parotid Neoplasms / radiotherapy. Sublingual Gland Neoplasms / drug therapy. Sublingual Gland Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Aged. Carcinoma, Adenoid Cystic / drug therapy. Carcinoma, Adenoid Cystic / radiotherapy. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Humans. Infusions, Intra-Arterial. Male. Middle Aged. Radiotherapy, Adjuvant. Taxoids / administration & dosage. Treatment Outcome

  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2000 Jan 22;355(9200):281-3 [10675076.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Mar;77(3):1561-5 [6103535.001]
  • [Cites] Cancer. 1991 Nov 1;68(9):1874-7 [1913539.001]
  • [Cites] Head Neck. 2000 Oct;22(7):687-93 [11002324.001]
  • [Cites] Arch Otolaryngol. 1982 Apr;108(4):221-4 [6280657.001]
  • [Cites] Cancer Sci. 2004 Aug;95(8):679-84 [15298732.001]
  • [Cites] Head Neck Surg. 1986 Nov-Dec;9(2):82-92 [3623942.001]
  • [Cites] Head Neck. 2002 Apr;24(4):406-10 [11933184.001]
  • [Cites] Anticancer Res. 2004 Nov-Dec;24(6):4135-40 [15736464.001]
  • [Cites] Cancer. 2001 Feb 1;91(3):541-7 [11169936.001]
  • [Cites] J Clin Oncol. 1987 Jun;5(6):951-5 [3585449.001]
  • [Cites] Head Neck. 2004 Aug;26(8):681-92; discussion 692-3 [15287035.001]
  • [Cites] Anticancer Res. 2000 Sep-Oct;20(5C):3781-3 [11268454.001]
  • [Cites] Head Neck. 2005 Jan;27(1):65-71 [15459915.001]
  • [Cites] Head Neck Surg. 1986 Jan-Feb;8(3):177-84 [3744850.001]
  • [Cites] Cancer Res. 1996 Apr 15;56(8):1842-50 [8620502.001]
  • (PMID = 17058139.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


14. Spyropoulou D, Vassiliou V, Tzelepi V, Kardari M, Tsamandas AC, Kardamakis D: Metastatic adenocarcinoma of parotid gland originating from the ampulla of vater: case report and review of the literature. J Gastrointest Cancer; 2007;38(2-4):95-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic adenocarcinoma of parotid gland originating from the ampulla of vater: case report and review of the literature.
  • AIM: To report a rare case of metastasis from an adenocarcinoma of the ampulla of Vater to the parotid gland.
  • PATIENTS AND METHODS: In February 2004, a 61-year-old male underwent Whipple surgery due to a grade II adenocarcinoma of the ampulla of Vater (stage IB:pT2N0M0).
  • Post surgery, the patient did not receive any adjuvant treatment, but was followed up regularly.
  • Two years post surgery, an abdominal computed tomography (CT) revealed metastatic hepatic lesions.
  • The patient subsequently underwent three lines of chemotherapy without significant response.
  • Two months after chemotherapy (April 2007), the patient complained of a painless lump in the parotid region that was progressing fast.
  • A head and neck CT depicted a 5 x 4 x 3 cm solid mass that was infiltrating the masseter and pterygoid muscles, the mandible, and parotid gland.
  • Fine needle aspiration showed that the infiltrating mass was due to an adenocarcinoma of the ampulla of Vater.
  • The patient subsequently received palliative radiotherapy (50.4 Gy), achieving a considerable therapeutic response.
  • CONCLUSIONS: Metastasis of adenocarcinoma of the ampulla of Vater to the parotid gland has not to our knowledge been previously reported.
  • [MeSH-major] Adenocarcinoma / secondary. Ampulla of Vater / pathology. Common Bile Duct Neoplasms / pathology. Parotid Neoplasms / secondary
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Humans. Male. Middle Aged. Radiotherapy Dosage. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1998 Jun;227(6):821-31 [9637545.001]
  • [Cites] Arch Surg. 1963 Nov;87:757-64 [14058839.001]
  • [Cites] Ann Surg. 1998 Jul;228(1):87-94 [9671071.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2004;11(5):301-9 [15549428.001]
  • [Cites] Surg Gynecol Obstet. 1993 Jan;176(1):33-8 [8093983.001]
  • [Cites] Ann Otolaryngol Chir Cervicofac. 2005 Feb;122(1):18-20 [15851941.001]
  • [Cites] Otolaryngol Head Neck Surg. 2006 Dec;135(6):844-8 [17141071.001]
  • [Cites] Dis Colon Rectum. 1985 Mar;28(3):190-2 [3971828.001]
  • [Cites] Ann Surg Oncol. 2003 Dec;10(10):1176-83 [14654474.001]
  • [Cites] Otolaryngol Pol. 2005;59(4):547-52 [16273860.001]
  • [Cites] J Surg Oncol. 1976;8(2):183-90 [1263521.001]
  • [Cites] Eur J Gastroenterol Hepatol. 1996 Feb;8(2):139-44 [8723418.001]
  • [Cites] Diagn Cytopathol. 2006 Aug;34(8):580-4 [16850487.001]
  • [Cites] J Surg Oncol. 2007 Mar 15;95(4):286-90 [17326125.001]
  • [Cites] Int J Urol. 2004 Oct;11(10):894-6 [15479296.001]
  • [Cites] Australas Radiol. 2004 Mar;48(1):88-92 [15027931.001]
  • [Cites] Acta Otorrinolaringol Esp. 2006 Jan;57(1):47-50 [16503033.001]
  • [Cites] Clin Transl Oncol. 2007 Apr;9(4):264-5 [17462982.001]
  • [Cites] Laryngoscope. 2003 Jun;113(6):1070-5 [12782825.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 2007;69(1):51-6 [17085953.001]
  • (PMID = 19016351.001).
  • [ISSN] 1941-6628
  • [Journal-full-title] Journal of gastrointestinal cancer
  • [ISO-abbreviation] J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


15. Charabi S, Balle V, Charabi B, Nielsen P, Thomsen J: Surgical outcome in malignant parotid tumours. Acta Otolaryngol Suppl; 2000;543:251-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical outcome in malignant parotid tumours.
  • Of 494 parotid gland tumours treated in Copenhagen county (population 600,000 inhabitants) in the period 1986-95, 50 patients (34 males, 16 females) had tumours that were proven to be malignant, making an incidence of 0.62/100,000/year.
  • The material included 41 primary parotid gland tumours, histologically the tumours were verified as mucoepidermoid carcinoma (n = 13), adenocarcinoma (n = 9), squamous cell carcinoma (n = 6), carcinoma ex pleomorph adenoma (n = 3), acinic cell carcinoma (n = 3), adenoid cystic carcinoma (n = 3) and other histological diagnoses (n = 4).
  • Primary malignant lymphoma of the parotid gland was diagnosed in six tumours and the last three tumours were metastatic carcinoma.
  • Four therapeutic modalities were applied: surgery only, surgery + radiation, surgery + chemotherapy, and surgery + chemotherapy + radiation.
  • [MeSH-major] Parotid Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Catchment Area (Health). Combined Modality Therapy. Denmark / epidemiology. Female. Humans. Male. Middle Aged. Neoplasm Staging. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10909035.001).
  • [ISSN] 0365-5237
  • [Journal-full-title] Acta oto-laryngologica. Supplementum
  • [ISO-abbreviation] Acta Otolaryngol Suppl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] NORWAY
  •  go-up   go-down


16. Shimizu A, Yamane M, Ito H, Araki S, Yoshida T, Suzuki M: [Clinicopathological study of salivary duct carcinoma]. Nihon Jibiinkoka Gakkai Kaiho; 2002 Jun;105(6):727-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We reviewed pathology in 49 cases of salivary adenocarcinoma, and diagnosed 6 cases as SDC.
  • All had a rapidly enlarged mass in the parotid gland.
  • Two had chemotherapy, but showed no effect.
  • [MeSH-major] Adenocarcinoma / pathology. Salivary Gland Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12138700.001).
  • [ISSN] 0030-6622
  • [Journal-full-title] Nihon Jibiinkoka Gakkai kaiho
  • [ISO-abbreviation] Nippon Jibiinkoka Gakkai Kaiho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proliferating Cell Nuclear Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


17. Hsi ED, Singleton TP, Swinnen L, Dunphy CH, Alkan S: Mucosa-associated lymphoid tissue-type lymphomas occurring in post-transplantation patients. Am J Surg Pathol; 2000 Jan;24(1):100-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucosa-associated lymphoid tissue-type lymphomas occurring in post-transplantation patients.
  • Extranodal marginal zone lymphomas of the mucosa-associated lymphoid tissue-type (MALT-type) have not been considered to be part of this spectrum.
  • Sites of lymphoma were the stomach in three patients and the parotid gland in two patients.
  • Mean time to the lymphoma was 84 months after transplantation.
  • All patients had morphologic features of low-grade extranodal marginal zone lymphomas of the MALT-type, and Helicobacter pylori was present in all three gastric cases.
  • These lymphomas were treated with a variety of modalities, including reduction of immunosuppression, antibiotics, surgical resection, radiation therapy, and chemotherapy.
  • At last follow-up, one patient had developed signet ring adenocarcinoma at 27 months but had no evidence of PTLD, one patient relapsed at 17 months but is alive with stable disease at 24 months, and the remaining patients were alive without disease at 11, 12, and 14 months.
  • Extranodal low-grade MALT-type lymphomas can occur in the post-transplantation setting and generally develop years after transplant.
  • These lymphomas appear to have more in common with MALT-type lymphomas in nonimmunocompromised patients than conventional PTLDs, although they occur in "at-risk" patients due to their immunosuppressive therapy.
  • Recognition of MALT-type lymphomas in the post-transplantation setting as an indolent disease avoids unnecessary treatment.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / etiology. Parotid Neoplasms / etiology. Stomach Neoplasms / etiology. Transplantation / adverse effects
  • [MeSH-minor] Combined Modality Therapy. Female. Flow Cytometry. Follow-Up Studies. Heart Transplantation / adverse effects. Herpesvirus 4, Human / genetics. Humans. Immunohistochemistry. Immunophenotyping. In Situ Hybridization. Kidney Transplantation / adverse effects. Liver Transplantation / adverse effects. Male. Middle Aged. Parotid Gland / pathology. RNA, Viral / analysis. Recurrence. Stomach / pathology. Survival Analysis. Time Factors

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10632493.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / RNA, Viral
  •  go-up   go-down


18. Husain A, Blumenschein G, Esmaeli B: Treatment and outcomes for metastatic sebaceous cell carcinoma of the eyelid. Int J Dermatol; 2008 Mar;47(3):276-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment and outcomes for metastatic sebaceous cell carcinoma of the eyelid.
  • Time from diagnosis of eyelid carcinoma to metastasis ranged from 0 to 62 months.
  • Treatment of regional nodal metastasis consisted of complete neck dissection followed by radiation therapy.
  • One patient developed lung metastasis 5 years after the diagnosis of eyelid tumor; she was treated with systemic chemotherapy followed by subtotal lung resection.
  • Systemic chemotherapy was considered for two additional patients: in one, chemotherapy was deferred due to poor performance status and ongoing medical problems; and another patient died before chemotherapy could be started.
  • The patient with bony metastasis was treated with radiation therapy to the spine.
  • The follow-up time from diagnosis of metastasis to last contact or death ranged from 1 month to 3 years (median of 21 months).
  • Metastasis can be discovered as late as 5 years after treatment of the eyelid carcinoma, warranting continued surveillance.
  • Treatment of metastatic disease may include a combination of chemotherapy, radiation, and surgical neck dissection.
  • [MeSH-major] Adenocarcinoma, Sebaceous / secondary. Bone Neoplasms / secondary. Eyelid Neoplasms / pathology. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Parotid Neoplasms / secondary. Sebaceous Gland Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18289332.001).
  • [ISSN] 1365-4632
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Maiuri F, Gangemi M, Giamundo A, Mariniello G, Colella A, Vergara P, Del Basso De Caro ML: Intracranial extension of salivary gland tumors. Clin Neuropathol; 2010 Jan-Feb;29(1):9-13
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial extension of salivary gland tumors.
  • OBJECTIVE: The aim of this report is to describe 3 cases of salivary gland tumors with intracranial extension associated to an extracerebral mass lesion, and to discuss the frequence, pathology and treatment of these very rare localizations.
  • The primary tumors were an adenocarcinoma and a malignant oncocytoma of the parotid gland and an adenoid cystic carcinoma of the submandibular gland.
  • Surgical treatment consisted in the seemingly complete removal of 2 tumors with middle fossa localization and partial removal of the cerebellopontine angle lesion.
  • Radiotherapy was administered in all 3 cases and chemotherapy in 2.
  • CONCLUSIONS: The intracranial extension of salivary gland tumors is a very rare event.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Brain Neoplasms / pathology. Carcinoma, Adenoid Cystic / pathology. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Brain / pathology. Fatal Outcome. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20040327.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


20. Kiprian D: [Strategy of combined treatment in patient with cancer of paranasal sinuses]. Otolaryngol Pol; 2007;61(4):527-30

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Strategy of combined treatment in patient with cancer of paranasal sinuses].
  • Other types of cancer in this region are adenocarcinoma (about 30%), carcinoma adenoides cysticum or neoplasms such as rhabdosarcoma, chondrosarcoma, lymphoma or melanoma malignum.
  • Metastases to the lymph nodes are seldom--below 30%; this is why elective lymphangiectomy or irradiation are not obligatory treatment in this case.
  • The treatment of cancers of paranasal sinuses is always surgery with adjuvant irradiation.
  • The modern radiotherapy techniques provide the possibility to spare healthy tissues and organs at risk.
  • The organs at risk in this localization are optical nerves and chiasm, and parotid glands.
  • The radiation treatment combined with chemotherapy is applied in cases of not radical surgery in the region of ethmoides sinuses.
  • [MeSH-major] Paranasal Sinus Neoplasms / diagnosis. Paranasal Sinus Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Incidence. Neoplasm Staging. Radiotherapy, Conformal. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18260245.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 5
  •  go-up   go-down


21. Kubota A, Furukawa M, Kawano T, Komatsu M: [Nedaplatin for recurrent cancer of the head and neck]. Nihon Jibiinkoka Gakkai Kaiho; 2004 May;107(5):475-82
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thirty-two patients, previously treated, (30 men and 2 women, mean age 59 years, twenty one with loco-regional recurrence and 11 with distant metastasis, 29 with squamous cell carcinoma, 2 with adenocarcinoma and one with adenoid cystic carcinoma) were treated with Nedaplatin (254-S) alone or combined with UFT.
  • The primary site was identified in the oropharynx in 8 patients, oral cavity in 7, larynx in 5, nasopharynx in 4, hypopharynx in 3, sinuses in one, parotid in one, and unknown primary in one patient.
  • Treatment with 254-S alone or combined UFT-E could be conducted in an outpatient setting and was able to improve the overall survival rate for recurrent head and neck cancer.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Head and Neck Neoplasms / drug therapy. Organoplatinum Compounds / therapeutic use
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Adenoid Cystic / drug therapy. Carcinoma, Squamous Cell / drug therapy. Female. Humans. Male. Middle Aged. Survival Rate. Tegafur / administration & dosage. Uracil / administration & dosage

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15198007.001).
  • [ISSN] 0030-6622
  • [Journal-full-title] Nihon Jibiinkoka Gakkai kaiho
  • [ISO-abbreviation] Nippon Jibiinkoka Gakkai Kaiho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 8UQ3W6JXAN / nedaplatin; 1-UFT protocol
  •  go-up   go-down


22. Numata T, Hiruma K, Tsukuda T, Asano T: [Malignant mixed tumor]. Gan To Kagaku Ryoho; 2004 Mar;31(3):314-7
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • According to the data of the Japanese committee on TNM classification for salivary gland carcinomas, carcinoma in pleomorphic adenoma accounted for about 10% of all salivary gland carcinomas, both in the parotid and submandibular glands.
  • The main type of carcinomas arising in pleomorphic adenoma were undifferentiated carcinoma, adenocarcinoma and squamous cell carcinoma.
  • The treatment of choice for carcinoma in pleomorphic adenoma has consisted of en-bloc excision with wide margin.
  • Invasive growth, facial nerve involvement, lymph node metastasis or high-grade malignant tumor are grounds for postoperative radiation therapy.
  • The role of chemotherapy has not yet been well established.
  • [MeSH-major] Mixed Tumor, Malignant. Salivary Gland Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15045931.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


23. Oudidi A, El-Alami MN, Boulaich M, Jazouli N, Kzadri M: [Primary sub-mandibular gland tumours: experience based on 68 cases]. Rev Laryngol Otol Rhinol (Bord); 2006;127(3):187-90
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary sub-mandibular gland tumours: experience based on 68 cases].
  • Sub-mandibulary gland tumours are less common than tumours of the parotid and pose many clinical and therapeutic challengers.
  • PATIENTS AND METHODS: Retrospective studies of sub-mandibular gland tumours presenting to our department between 1986 and 2000.
  • Definitive diagnosis was by complete excision and pathological examination.
  • For malignant lesions (n= 31) the most frequent were: Adenoid cystic carcinoma (n= 10), epidermoid carcinoma (n= 5), adenocarcinoma (n= 5), mucoepidermoid carcinoma (n= 3), malignant non Hodgkinien lymphoma (n= 5).
  • Treatment was by total surgical excision of the submandibular gland for the begnin tumours.
  • Radiotherapy was performed in 24 cases and chemotherapy in 10 cases.
  • CONCLUSION: Malignity in sub-mandibular gland tumours is more frequent than in the parotid gland.
  • [MeSH-major] Submandibular Gland Neoplasms / classification. Submandibular Gland Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17007195.001).
  • [ISSN] 0035-1334
  • [Journal-full-title] Revue de laryngologie - otologie - rhinologie
  • [ISO-abbreviation] Rev Laryngol Otol Rhinol (Bord)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


24. Locati LD, Quattrone P, Bossi P, Marchianò AV, Cantù G, Licitra L: A complete remission with androgen-deprivation therapy in a recurrent androgen receptor-expressing adenocarcinoma of the parotid gland. Ann Oncol; 2003 Aug;14(8):1327-8
Hazardous Substances Data Bank. BICALUTAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A complete remission with androgen-deprivation therapy in a recurrent androgen receptor-expressing adenocarcinoma of the parotid gland.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12881399.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Case Reports; Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Anilides; 0 / Nitriles; 0 / Receptors, Androgen; 0 / Tosyl Compounds; 57773-63-4 / Triptorelin Pamoate; A0Z3NAU9DP / bicalutamide
  •  go-up   go-down


25. Takane H, Nosaka A, Wakushima H, Hosokawa K, Ieiri I: Rifampin reduces the analgesic effect of transdermal fentanyl. Ann Pharmacother; 2005 Dec;39(12):2139-40
Hazardous Substances Data Bank. FENTANYL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Analgesics, Opioid / antagonists & inhibitors. Analgesics, Opioid / therapeutic use. Antibiotics, Antitubercular / adverse effects. Fentanyl / antagonists & inhibitors. Fentanyl / therapeutic use. Pain / drug therapy. Rifampin / adverse effects
  • [MeSH-minor] Adenocarcinoma / pathology. Administration, Cutaneous. Aged. Drug Interactions. Humans. Lung Neoplasms / complications. Lung Neoplasms / secondary. Male. Parotid Neoplasms / pathology. Tuberculosis, Pulmonary / complications. Tuberculosis, Pulmonary / drug therapy

  • MedlinePlus Health Information. consumer health - Pain.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RIFAMPIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16288064.001).
  • [ISSN] 1060-0280
  • [Journal-full-title] The Annals of pharmacotherapy
  • [ISO-abbreviation] Ann Pharmacother
  • [Language] eng
  • [Publication-type] Case Reports; Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 0 / Antibiotics, Antitubercular; UF599785JZ / Fentanyl; VJT6J7R4TR / Rifampin
  •  go-up   go-down






Advertisement